Elacestrant

FDA Drug Profile — ORSERDU

Elacestrant is listed in the FDA National Drug Code directory with 6 NDC codes, marketed under brand name including ORSERDU. Available dosage form: tablet, film coated.

Drug details

Generic Name
Elacestrant
Brand Names
ORSERDU
Application Number
NDA217639
Sponsor
Stemline Therapeutics, Inc.
NDC Codes
6
Dosage Forms
TABLET, FILM COATED
Routes
ORAL
Active Ingredients
ELACESTRANT

Indications and Usage

1 INDICATIONS AND USAGE ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)‑negative, ESR1 -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test [see Dosage and Administration ( 2.1 )] , with disease progression following at least one line of endocrine therapy. ORSERDU is an estrogen receptor antagonist indicated for: treatment of postmenopausal women or adult men, with ER-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.